The nose is essential
HNO. 2024 Apr;72(4):223-224. doi: 10.1007/s00106-024-01444-9. Epub 2024 Mar 22.NO ABSTRACTPMID:38519753 | DOI:10.1007/s00106-024-01444-9 (Source: HNO)
Source: HNO - March 23, 2024 Category: ENT & OMF Authors: Rainer K Weber Source Type: research
Crossing Borders: interdisciplinary, international, interactive : 95th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery 2024 in Essen
HNO. 2024 Apr;72(4):221-222. doi: 10.1007/s00106-024-01445-8. Epub 2024 Mar 22.NO ABSTRACTPMID:38519752 | DOI:10.1007/s00106-024-01445-8 (Source: HNO)
Source: HNO - March 23, 2024 Category: ENT & OMF Authors: Stephan Lang Source Type: research
The nose is essential
HNO. 2024 Apr;72(4):223-224. doi: 10.1007/s00106-024-01444-9. Epub 2024 Mar 22.NO ABSTRACTPMID:38519753 | DOI:10.1007/s00106-024-01444-9 (Source: HNO)
Source: HNO - March 23, 2024 Category: ENT & OMF Authors: Rainer K Weber Source Type: research
Sudden-onset double vision-a complication requiring interdisciplinary treatment
HNO. 2024 Mar 18. doi: 10.1007/s00106-024-01450-x. Online ahead of print.NO ABSTRACTPMID:38498175 | DOI:10.1007/s00106-024-01450-x (Source: HNO)
Source: HNO - March 18, 2024 Category: ENT & OMF Authors: C Schmit A Runge A J öbstl G Widmann J Schmutzhard B Hofauer Source Type: research
Difficult-to-treat chronic rhinosinusitis-when the standard treatment is not effective and biologics are not available
CONCLUSION: To accurately assess the efficacy of second-line therapies for treatment of difficult-to-treat CRS within an endotype-specific framework, additional controlled clinical trials are needed that take into account the heterogeneity of CRS endotypes.PMID:38472346 | DOI:10.1007/s00106-024-01443-w (Source: HNO)
Source: HNO - March 13, 2024 Category: ENT & OMF Authors: Robert B öscke Source Type: research
Biologic therapy in patients with severe NSAID-exacerbated respiratory disease and previous aspirin desensitization : Results of a multicentric study
CONCLUSION: Add-on biologic therapy is effective, safe, and widely accepted among CRSwNP + NERD patients. Future studies might allow for personalized algorithms with sequential surgery, ATAD, and/or biologic therapy.PMID:38466409 | DOI:10.1007/s00106-024-01433-y (Source: HNO)
Source: HNO - March 11, 2024 Category: ENT & OMF Authors: Anna-Rebekka Staufenberg Hanna K Frankenberger Ulrike F örster-Ruhrmann Franziska C Spahn Ludger Klimek Kai Fruth Clemens Stihl Christoph Matthias Moritz Gr öger Jan Hagemann Source Type: research
